Advertisement
Advertisement
CUVL
Clinuvel Pharmaceuticals Limited - ADR
5.19
USDSponsored
+0.01
+0.19%
Nov 10, 15:59 UTC -5
Closed
After-Market
5.23
+0.04
+0.73%
Clinuvel Pharmaceuticals Limited - ADR (CUVL) Earnings
CUVL Earnings Reports
Positive Surprise Ratio
CUVL beat 0 of 1 last estimates.
0%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q2 27 (Revenue/ EPS)
$36.49M
/$0.27
Implied change from Q4 26 (Revenue/ EPS)
-36.08%
/-41.30%
Implied change from Q2 26 (Revenue/ EPS)
--
/+35.00%
Clinuvel Pharmaceuticals Limited - ADR earnings per share and revenue
On Aug 27, 2026, CUVL reported earnings of 0.46 USD per share (EPS) for Q4 26, missing the estimate of 0.50 USD, resulting in a -8.79% surprise. Revenue reached 57.09 million, compared to an expected 61.24 million, with a -6.77% difference. The market reacted with a -11.44% price change (close before vs. close after earnings).
Looking ahead to Q2 27, -- analysts forecast an EPS of 0.27 USD, with revenue projected to reach 36.49 million USD, implying an decrease of -41.30% EPS, and decrease of -36.08% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Clinuvel Pharmaceuticals Limited - ADR's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, Clinuvel Pharmaceuticals Limited - ADR reported EPS of $0.46, missing estimates by -8.79%, and revenue of $57.09M, -6.77% below expectations.
How did the market react to Clinuvel Pharmaceuticals Limited - ADR's Q4 2026 earnings?
The stock price moved down -11.44%, changed from $7.64 before the earnings release to $6.77 the day after.
When is Clinuvel Pharmaceuticals Limited - ADR expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Clinuvel Pharmaceuticals Limited - ADR's next earnings report?
Based on --
analysts, Clinuvel Pharmaceuticals Limited - ADR is expected to report EPS of $0.27 and revenue of $36.49M for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.